EARLY RESOLUTION OF TALQUETAMAB ORAL SIDE EFFECTS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED WATERLESS EMPIRICAL TASTE TEST (WETT) AND PATIENT REPORTED OUTCOMES (PRO) DATA FROM TALISMAN

@article{donk2026early,
  title = {{EARLY RESOLUTION OF TALQUETAMAB ORAL SIDE EFFECTS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED WATERLESS EMPIRICAL TASTE TEST (WETT) AND PATIENT REPORTED OUTCOMES (PRO) DATA FROM TALISMAN}},
  author = {Niels Wcj VAN DE DONK and Rakesh POPAT and Beth FAIMAN and Junichiro YUDA and Kihyun KIM and Abel DA COSTA and Alexa LAHEIJ and Richard DOTY and James OMEL and Brea LIPE and Larysa SANCHEZ and Ajai CHARI and Alexander LIN and Herve SROUSSI and Mariana FERNANDEZ and Kathleen S GRAY and Svetlana GAVRILOV and Gloria AGUILAR and Kasey BOLYARD and Jennifer SCHULTZ and Keqin QI and Diana CORTES-SELVA and Jacqueline FABRY and Sheri SKERGET and Jenny ZHANG and Chris HEUCK and Kelly HAWKS and Mark WILDGUST and Lori PARISI and Leo RASCHE},
  journal = {Hematology, Transfusion and Cell Therapy},
  year = {2026},
  month = oct,
  doi = {10.1016/j.htct.2026.107867},
  url = {https://doi.org/10.1016/j.htct.2026.107867},
  note = {CC BY},
}

TY  - JOUR
TI  - EARLY RESOLUTION OF TALQUETAMAB ORAL SIDE EFFECTS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED WATERLESS EMPIRICAL TASTE TEST (WETT) AND PATIENT REPORTED OUTCOMES (PRO) DATA FROM TALISMAN
AU  - Niels Wcj VAN DE DONK
AU  - Rakesh POPAT
AU  - Beth FAIMAN
AU  - Junichiro YUDA
AU  - Kihyun KIM
AU  - Abel DA COSTA
AU  - Alexa LAHEIJ
AU  - Richard DOTY
AU  - James OMEL
AU  - Brea LIPE
AU  - Larysa SANCHEZ
AU  - Ajai CHARI
AU  - Alexander LIN
AU  - Herve SROUSSI
AU  - Mariana FERNANDEZ
AU  - Kathleen S GRAY
AU  - Svetlana GAVRILOV
AU  - Gloria AGUILAR
AU  - Kasey BOLYARD
AU  - Jennifer SCHULTZ
AU  - Keqin QI
AU  - Diana CORTES-SELVA
AU  - Jacqueline FABRY
AU  - Sheri SKERGET
AU  - Jenny ZHANG
AU  - Chris HEUCK
AU  - Kelly HAWKS
AU  - Mark WILDGUST
AU  - Lori PARISI
AU  - Leo RASCHE
PY  - 2026
DA  - 2026/10/23
JO  - Hematology, Transfusion and Cell Therapy
DO  - 10.1016/j.htct.2026.107867
UR  - https://doi.org/10.1016/j.htct.2026.107867
AB  - Background: In the phase 1/2 MonumenTAL-1 study, talquetamab (Tal) achieved high response rates and durable survival in RRMM. Although taste changes and other oral toxicities are common, their longitudinal assessment remains limited. The WETT is a novel tool that objectively measures dysgeusia onset, severity, and resolution and evaluates prophylactic interventions. Initial TALisman results showed early dysgeusia onset (∼2 weeks) with improvement beginning after 3 months. Here, we report updated TALisman results with extended follow-up and a 3-month futility analysis of dexamethasone oral rinse prophylaxis (prophy Dex) versus control. Methods: TALisman (NCT06500884) is an ongoing phase 2 study in RRMM patients previously exposed to a PI, IMiD, and anti-CD38 antibody. Patients with severe baseline dysgeusia (per WETT) are excluded. Participants are randomized to control or experimental prophylaxis (eg, dexamethasone) for Tal-related oral toxicities starting 7 days before the first step-up dose and are assessed longitudinally. Patients achieving ≥VGPR may reduce talquetamab dosing from 0.8 mg/kg Q2W to Q4W from cycle 5. Co-primary endpoints are dysgeusia incidence, severity, time to first severe dysgeusia, and dysgeusia improvement/resolution at 3 and 6 months per WETT. Results: As of December 2025, 30 pts were randomized (15 per group) median age was 62.5 years; 56.7% were male. 25 pts completed ≥3 cycles and 11 completed ≥6 cycles. Overall 86.7% had dysgeusia and 76.7% had severe dysgeusia at any time point. The highest proportion of pts with any grade dysgeusia occurred at C3D8 with the control (80.0%) and at C2D1 with prophy Dex (92.3%). Median time to first dysgeusia was 15 days (control) and 8 days (prophy Dex) median time to first severe dysgeusia was 68 days and 9 days, respectively. Prophy Dex did not result in improved outcomes vs the control in a futility analysis at the end of month 3 improvement/resolution of dysgeusia was observed in 63.6% (control) vs 27.3% (prophy Dex) at the end of month 3, and in 60.0% vs 40.0% respectively, at the end of month 5. Overall, the highest proportion of pts with severe dysgeusia (∼60%) by WETT was detected earlier (C1D15) vs severe/complete loss by the Scale of Subjective Total Taste Acuity (STTA; C4D1). Additional safety, PRO, and salivary data, and initial pregabalin prophylaxis data, will be presented at the congress. Conclusion: TALisman data confirm that dysgeusia measured by WETT begins to improve/resolve after 3 months of Tal, with 60% showing improvement/resolution at the end of 5 months. Severe dysgeusia measured by objective WETT preceded subjective severe/complete loss by STTA. Prophy Dex did not improve rates of dysgeusia resolution, although small numbers limit definitive conclusions. Emerging data from TALisman help to inform management strategies and clarify expectations for pts, caregivers, and healthcare providers to facilitate ongoing treatment and clinical benefit from Tal. TALisman is ongoing and exploring additional interventions to prevent dysgeusia and improve pt experience.
SN  - 2531-1379
SN  - 2531-1387
ER  -